InMed Pharmaceuticals Inc. (INM)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.36 on 9 Oct 2026

26 buys0 sales at will0 planned sales

Key numbers

Fiscal year 2025, ended 30 Jun 2025, as filed

Revenue

$4.94M

Net income

$8.16M

Free cash flow

$8.10M

Gross margin

34.5%

Net margin

-165.1%

Return on equity

-60.8%

Revenue growth, 1 yr

7.5%

Revenue and net income

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first

All of them →

Date	Insider	Type	Value	Of own stake
8 Oct 2026	ADAR1 Capital Management, LLC 10% owner	Bought	$3.00K	0.2%
7 Oct 2026	ADAR1 Capital Management, LLC 10% owner	Bought	$4.05K	0.3%
6 Oct 2026	ADAR1 Capital Management, LLC 10% owner	Bought	$7.44K	0.6%
5 Oct 2026	ADAR1 Capital Management, LLC 10% owner	Bought	$24.18K	2.0%
2 Oct 2026	ADAR1 Capital Management, LLC 10% owner	Bought	$11.05K	0.9%
1 Oct 2026	ADAR1 Capital Management, LLC 10% owner	Bought	$21.85K	1.8%

Clue Score

How it works

66out of 100

Profitability 20

Financial strength 67

Growth 100

Insiders 93

Strongest on growth (100), weakest on profitability (20). A score of the business, not of the price.

What insiders did

Last 12 months

Only here

Bought

$1.35M

26 buys, 2 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan

Every insider, every trade →

Profile

Sector: Health care
Industry: Pharmaceutical Preparations
Country: British Columbia, Canada
SEC filings: EDGAR →